Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of drug delivery technologist Flamel Technologies
So what: This is splash damage from sector news: Smaller rival Emisphere Technologies was just told by Novartis
Now what: Like Lady Luck, the FDA can be fickle. The Emisphere effect will soon fade from Flamel's chart as investors refocus on the company's pipeline of intravenous drugs to modify for simpler and cheaper subcutaneous injections. Flamel has a healthy relationship (pun intended) with major partner GlaxoSmithKline
Interested in more info about Flamel? Click here to add it to My Watchlist.
Fool contributor Anders Bylund holds no position in any of the companies mentioned. Motley Fool newsletter services have recommended buying shares of Novartis and GlaxoSmithKline. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinion, but we all believe that considering a diverse range of insights makes us better investors. Check out Anders' holdings and bio, or follow him on Twitter and Google+. We have a disclosure policy.